Prof. Priv. Doz. Dr. Nika Skoro-Sajer - Zu meiner Person

Ich wurde am 7.Oktober 1972 in Zagreb (Kroatien) geboren und bin österreichische Staatsbürgerin, verheiratet und Mutter von drei Kindern: Luka (2000), Laura (2005) und Lea-Marie (2013).

Universitätsausbildung

  • 1991-1994 Medizinische Fakultät, Universität Zagreb
  • 1994-1998 Medizinische Fakultät, Universität Wien
  • Promotion  an der Medizinischen Fakultät Wien am 16. Juli 1998 mit Notendurchschnitt 1.16

Schulbildung

  • 20. Mai 1991   Matura mit Auszeichnung, Klassisches Gymnasium, Zagreb

Berufserfahrung

  • 1992-1994 Demonstrator am Institut für Anatomie; Demonstrator am Institut für Histologie und Embryologie; Demonstrator am Institut für Physiologie, Medizinische Fakultät, Universität Zagreb, Kroatien
  • 1998-2002 Wissenschaftliche Mitarbeiterin an der Universitätsklinik für Innere Medizin II und IV, unter der Leitung von Prof. Dr. Irene Lang und Prof. Dr. Meinhard Kneussl
  • Seit 2002 Arzt in Ausbildung an der Universitätsklinik für Innere Medizin, Abteilung für Kardiologie unter der Leitung von Prof. Dr. G. Maurer
  • Seit 2004  Selbständige ärztliche Tätigkeit in der Lungenhochdruckambulanz, Abteilung für Kardiologie
  • 2009  Facharztdiplom für Innere Medizin

  • 2010 Venia docendi für Innere Medizin Habilitationsthema: „Assessment of secondary vascular changes of chronic thromboembolic pulmonary hypertension and their implications for treatment“

  • 2015 Zusatzfacharztdiplom für Kardiologie
  • Seit 2016 Interventionelle Kardiologin
  • 2018 Associate Professor auf MUW
  • 2019 MBA Health Management
  • Seit 2019 Stellvertretende Leitung der Lungenhochdruckambulanz

Andere Aktivitäten

  • 2008-2012 Arbeitsleiterin des Arbeitskreises „Pulmonale Zirkulation“ bei Österreichischer Gesellschaft für Pneumologie (ÖGP)

    Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • 2014-2016 Arbeitsleiterin des „Kardiopulmonalen Arbeitskreises“ bei Österreichischer Kardiologischer Gesellschaft (ÖKG)
  • 2010-2023 Reviewer für:
    • European Respiratory Journal,
    • European Heart Journal,
    • International Journal of Cardiology,
    • Expert Opinion on Orphan Diseases,
    • Respiratory Disease,
    • Journal of Heart and Lung Transplantation,
    • Thrombosis and Haemostasis,
    • Pulmonary Circulation,
    • Respiration,
    • Expert Opinion on Drug Metabolism and Toxicology,
    • American Journal of Cardiovascular Drugs,
    • Thorax
  • Seit 2023 Arbeitsleiterin des "Kardiopulmonalen Arbeitskreises" bei Österreichischer Kardiologischer Gesellschaft (ÖKG)

Wissenschaftliche Auszeichnungen

  • 2004 und 2006 Altana travel award for American Thoracic Society

  • 2007 The best abstract of the Moderated Poster Session, European Society of Cardiology 2007

  • 2008 Österreichischer Kardiologenpreis 2008

  • 2009 Forschungspreis der Erste Bank

  • 2009 Österreichischer Kardiologenpreis 2009

  • 2009 Silver sponsorship bei European Respiratory Society 2009

  • 2009 Posterpreis bei 2nd Annual Central Europe PAH Meeting

  • 2010 Forschungspreis der René Baumgart-Stiftung

  • 2017 Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der

    Bundeshauptstadt Wien                  

Publikationen:

 

1.       The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy

M. Laggner, P. Hacker, F. Oberndorfer, J. Bauer, T. Raunegger, C. Gerges, T. Szerafin,  J. Thanner, IM Lang, N. Skoro-Sajer, HJ Ankersmit, B. Moser.

Biology (Basel). 2022 Jan. 12; 11(1): 118.  doi: 10.3390/biology11010118.

 

2.       Chronic Thromboembolic Pulmonary Disease and Chronic Thromboembolic Pulmonary Hypertension.

Lang IM, Campean IA, Sadushi-Kolici R, Badr-Eslam R, Gerges C, Skoro-Sajer N.

 

Clin Chest Med. 2021 Mar; 42(1):81-90.doi: 10.1016/j.ccm.2020.11.014. Epub 2021 Jan  12.

 

3.       Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension.

C. Gerges, R. Friewald, M. Gerges, I. Shafran, R. Sadushi-Kolici, N. Skoro-Sajer, B. Moser, S. Taghavi, W.Klepetko, IM Lang.

Circ Cardiovasc Interv. 2021 Aug; 14(8): e010243.doi:10.1161/CIRCINTERVENTIONS.120.010243. Epub 2021 Jul 16.

 

4.       Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension: Hemodynamic Phenotyping and Histomorphometric Assesment. 

G. Gerges, M. Gerges, R. Friewald, P. Fesler, P. Dorfmüller, S. Sharma, K. Karlocai, N. Skoro-Sajer, J. Jakowitsch, B. Moser, S. Taghavi, W. Klepetko, IM Lang.

Circulation. 2020 Feb. 4; 141(5): 376-386.  

 

5.       The effects of parenteral prostacycline therapy as add-on treatment to oral compounds in Eisenmenger syndrome.

M. D’Alto, A. Constantine, O.H. Balint, E. Romeo, P. Argiento, L. Ablonczy, N. Skoro-Sajer, G. Giannakoulas, K. Dimopoulos.

Eur Respir J. 2019 Aug. 14. pii: 1901401. doi: 10.1183/13993003.01401-2019.

 

6.       Subcutaneous treprosinil for the treatment of severe non-operable chronic

thromboembolic pulmonary hypertension (CTREPH): a double blind, phase 3, randomised controlled trial.

R. Sadushi-Kolici, P. Jansa, G. Kopec, A. Torbicki, N. Skoro-Sajer, I.A. Campean, M. Halank, I. Simkova, K. Karlocai, R. Steringer-Mascherbauer, M. Samarzija, B. Salobir, W. Klepetko, J. Linder,  I.M. Lang.  

Lancet Respir Med. 2019 Mar;7(3):239-248.

 

7.       Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary   hypertension– sampling plasma and surgical specimens.

N. Skoro-Sajer, C. Gerges, M. Gerges, A. Panzenböck, J. Jakowitsch, A. Kurz, S. Taghavi, R. Sadushi-Kolici, I. Campean, W. Klepetko, D.S. Celermajer, I.M. Lang.

     J Heart Lung Transplant. 2018 Sep;37(9):1067-1074.

 

8.       Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension.

N. Skoro-Sajer, C. Gerges, O.H. Balint, D Kohalmi, M. Kaldararova, I. Simkova, J. Jakowitsch, H. Gabriel, H. Baumgartner, M. Gerges, R. Sadushi-Kolici, D.S. Celermajer, I.M. Lang. Heart. 2018 Jul;104(14):1195-1199.

 

9.       A case of lifelong myocardial ischaemia. 

Skoro-Sajer N, Graf S, Gerges C, Lang IM.

Eur Heart J Cardiovascular Imaging.  2016 Aug;17(8):949

 

10.    Hemodynamic thresholds for pre-capillary pulmonary hypertension.

C. Gerges, M. Gerges, N. Skoro-Sajer, Y. Zhou, L. Zhang, R. Sadushi-Kolici, J. Jakowitsch, M. I. Lang.

Chest 2015. Apr;149(4):1061-73.

 

11.    Right ventricle in acute and chronic pulmonary (2013 Grover Conference series).

C. Gerges, N. Skoro-Sajer, I.Lang.

Pulm Circ. 2014 Sep; 4(3):378-86.

 

12.    Extended-release oral Treprostinil for the treatment of pulmonary arterial hypertension.

N. Skoro-Sajer, I.Lang.

Expert Rev Cardiovascular Ther. 2014 Dec;12(12):1391-9.

 

13.    Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH.

B. Moser, A. Megerle, C. Bekos, S. Janik, T. Szerafin, P. Birner, A.I. Schiefer, M. Mildner, I. Lang, N.Skoro-Sajer, R. Sadushi-Kolici, S. Taghavi, W. Klepetko, H.J. Ankersmit.

PLoS One. 2014 Sep 4;9(9):e106440. doi: 10.1371/journal.pone.0106440.             IF 3.534

 

14.    2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The       Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS).

Authors/Task Force Members, Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman M, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Noordegraaf AV, Zamorano JL, Zompatori M; Authors/Task Force Members.

Eur Heart J. 2014 Aug 29. pii: ehu283. [Epub ahead of print]                            IF 14.723

 

15.    Selexipag for the treatment of pulmonary arterial hypertension.

N. Skoro-Sajer, I.M. Lang.

Expert Opin Pharmacother. 2014 Feb; 15(3):429-36.                          IF 2.86

 

16.    Surgical specimens, hemodynamics and long-term outcomes after pulmonary endarterectomy.

N. Skoro-Sajer, G. Marta, C. Gerges, G. Hlavin, P. Nierlich, S. Taghavi, R. Sadushi-Kolici, W. Klepetko, I.M. Lang.

Thorax. 2014 Feb; 69(2): 116-22.                                                                  IF 8.562

 

17.    Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.

N. Skoro-Sajer.

Drugs 2012 Dec 24;72(18):2351-63.                                                              IF 4.133

 

18.    Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.

R. Sadushi-Kolici, N. Skoro-Sajer, D. Zimmer, D. Bonderman, M. Schemper, W. Klepetko, J. Jakowitsch, I.M. Lang.

J Heart Lung Transplant. 2012 Jul; 31(7): 735-43.                                        IF 5.611

 

19.    A noninvasive algorithm to exclude pre-capillary pulmonary hypertension.

D. Bonderman, P. Wexberg, AM Martischnig, H. Heinzl, MB Lang, R. Sadushi-Kolici, N. Skoro-Sajer, Lang IM.

Eur Respir J. 2011 May; 37 (5): 1096-103.                                                     IF 7.125

 

20.    Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension-a pilot study.

N. Skoro-Sajer, N. Hack, R. Sadushi-Kolici, D. Bonderman, J. Jakowitsch, W. Klepetko, M.A.R. Hoda, M. Kneussl, I.M. Lang.

Circulation 2009 Jan; 119(2): 298-305.                                                          IF 14.948

 

21.    Treprostinil for Pulmonary hypertension.

N.Skoro-Sajer, I.M. Lang, R. Naeije.  

Vascular Health and Risk Management 2008; 4(3):507-13.

 

22.    Risk factors for chronic thromboembolic pulmonary hypertension.

D. Bonderman, H. Wilkens, S. Wakounig, H.J. Schäfers, P. Jansa, J. Lindner, I. Simkova, A.M. Martischnig, J. Dudczak, R. Sadushi, N. Skoro-Sajer, W. Klepetko, I.M. Lang. 

Eur Respir J. 2009 Feb; 33(2): 325-31.                                                          IF 7.125

 

23.    A clinical Comparison of Slow- and Rapid-Escalation Treprostinil Dosing Regimens in Patients with Pulmonary Hypertension (PH).

N. Skoro-Sajer, I.M. Lang, E. Harja, M. Kneussl, W.G. Sing, J.S. Gibbs. 

Clinical Pharmacokinetics 2008; 47(9): 611-8.                                     IF 5.486

 

24.    The Role of Treprostinil Sodium in the Management of Pulmonary Arterial Hypertension. N.Skoro-Sajer, I.M. Lang.

Am J Cardiovasc Drugs 2008;8(4):213-7.

 

25.    Treprostinil for the treatment of pulmonary hypertension. 

N.Skoro-Sajer, I.M. Lang.

Expert Opinion on Pharmacotherapy 2008;9(8):1415-20.                              IF 2.203

 

26.    Heart-Type Fatty Acid-Binding Protein for Risk Assessment of Chronic Thromboembolic Pulmonary Hypertension.

M. Lankeit, C. Dellas , A. Panzenböck, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schäfer, M. Puls, S. Konstantinides, I. M. Lang.

Eur Respir J. 2008 May; 31(5): 1024-9.                                                         IF 7.125

 

27.    Asymmetric Dimethylarginine (ADMA) in Chronic Thromboembolic Pulmonary Hypertension.

N. Skoro-Sajer, F. Mittermayer, D. Bonderman, M.Wolzt, M. Kneussl, I.M. Lang.

Am J Resp Crit Care Med. 2007 Dec 1; 176(11): 1156-60.                    IF 11.986

 

28.    Predictors of outcome in Chronic Thromboembolic Pulmonary Hypertension.

D. Bonderman, N. Skoro-Sajer, J. Jakowitsch, C. Adlbrecht, D. Dunkler, S. Taghavi, W. Klepetko, M. Kneussl, I.M. Lang.

Circulation. 2007 Apr 24; 115(16): 2153-8.                                                    IF 14.948

 

29.    Treprostinil for severe inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

N.Skoro-Sajer, D.Bonderman, F. Wiesbauer, E. Harja, J. Jakowitsch, W. Klepetko, M. Kneussl, I.M. Lang.

J Thromb Haemost. 2007 Mar; 5(3): 483-9.                                                    IF 5.55

 

30.    Bosentan therapy for inoperable Chronic Thromboembolic Pulmonary Hypertension.

D. Bonderman, R. Nowotny, N. Skoro-Sajer, J. Jakowitsch, C. Adlbrecht, W. Klepetko, I.M. Lang.

Chest. 2005 Oct;128(4):2599-603.                                                                  IF 5.85

 

31.    Efficacy of long-term subcutaneous Treprostinil sodium in Pulmonary Hypertension.

I.M. Lang, M. Gomez-Sanchez, M. Kneussl, R. Naeije, P. Escribano,  N. Skoro- Sajer, J.L. Vachiery.

Chest. 2006 Jun; 129 (6):1636-43.                                                                 IF 5.85

 

32.    Bosentan therapy for Pulmonary Arterial Hypertension associated with Hereditary Haemorrhagic Telangiectasia.

D. Bonderman, R. Nowotny, N. Skoro-Sajer, C. Adlbrecht,  I.M. Lang.

Eur J Clin Invest. 2006 Sep; 36 Suppl 3:71-2.                                                 IF 2.834

 

33.    Longitudinal Analysis of Perfusion lung Scintigrams of Patients with unoperated Chronic Thromboembolic Pulmonary Hypertension.

N.Skoro-Sajer, A.Becherer, W. Klepetko, M. Kneussl, I.M. Lang.

Thromb Haemost. 2004 Jul; 92(1): 201-7.                                                      IF 5.760

 

34.    Pulmonary hypertension in rheumatic diseases.

I.M. Lang, D. Bonderman, N.Skoro-Sajer, W. Klepetko, M. Kneussl.

Z. Rheumatol. 2003 Feb; 62 (1):2-9.

Invited Talks at International Scientific Meetings

1.     Perfusion Lung Scintigrams in Chronic Thromboembolic Pulmonary Hypertension.

Pulmonary Hypertension Meeting,

March 16, 2002, Lech an Arlberg, Austria

 

2.     Assessment of Dynamic Changes in Perfusion Lung Scintigrams of Patients with Chronic Thromboembolic Pulmonary Hypertension.

Conference of European Respiratory Society,

September 15, 2002, Stockholm, Sweden.

 

3.     Long-term subcutaneous treprostinil therapy for pulmonary arterial hypertension.

European Society of Cardiology 2003,

September 1, 2003, Vienna, Austria.

 

4.     Plasma brain natriuretic peptide (BNP) in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil.

Conference of American Thoracic Society 2004.

May 22, 2004, Orlando, USA.

 

5.     A Clinical Comparison of Slow and Rapid-Escalation Treprostinil Dosing Regimens in Patients with Pulmonary Arterial Hypertension.

Conference of European Respiratory Society

September 18, 2005, Copenhagen, Denmark.

 

6.     Patient mit Dyspnoe.

Collegium Publicum. March, 31, 2006, Vienna Austria.

 

7.     L-arginine, Symmetric (SDMA), Asymmetric Dimethylarginine (ADMA) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Conference of American Thoracic Society.

May 23, 2006, San Diego, USA.

 

8.     Pulmonary vascular reactivity and prognosis in chronic thromboembolic pulmonary hypertension (CTEPH).

Conference of European Society of Cardiology-best abstract.

September, 3, 2007, Vienna, Austria.

 

9.     Pulmonary vascular reactivity and prognosis in chronic thromboembolic pulmonary hypertension (CTEPH).

American Heart Association 2007,

November 3, 2007, Orlando, USA.

 

10.  PAH aus Sicht des spezialisierten Zentrums.

Österreichische Gesellschaft für Allgemeine und Familienmedizin 2007.

June, 1, 2007, Vienna, Austria.

 

11.  L-arginine, Symmetric (SDMA), Asymmetric Dimethylarginine (ADMA) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Jahrestagung der Österrichischen Kardiologischen Gesellschaft – Best abstracts Session. 

June 1, 2008, Salzburg, Austria

 

12.  Frühe Therapie bei Lungenhochdruck.

Jahrestagung der Österreichischen Gesellschaft für Pulmologie

September 10, 2009, Vienna, Austria.

 

13.  Initiation of parenteral prostanoid therapy for PH remains time critical; patient selection and treatment algorithms of a major reference center.

1st  Annual Central European PAH Meeting

November 22, 2008, Salzburg, Austria

 

14.  Subcutaneous Treprostinil in the Management of Pulmonary Arterial Hypertension.

Annual Congress of Serbian Pulmonologists – Pulmonary Hypertension

October, 16, 2009, Belgrade, Serbia

 

15.  Estimating mean Pulmonary Arterial Pressure in Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Conference of European Respiratory Society.

September 13, 2009, Vienna, Austria.

 

16.  D-Dimer in Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Conference of European Respiratory Society.

September, 12, 2009, Vienna, Austria.

 

17.  Long-term follow-up on Patient in Vienna. 

Nordic Region Pulmonary Arterial Hypertension, Experts’ Meeting,

September 22, 2009, Copenhagen, Norway

 

18.  Mechanisms of prostacyclin actions: old and new pathways

3rd Annual Central European PAH Meeting

November 27, 2010, Salzburg, Austria

 

19.  Pharmakologische Möglichkeiten der pulmonalarteriellen Drucksenkung: Was ist gesichert?

42. Jahrestagung der DGIIN und der ÖGIAIM in Berlin

June 9, 2010, Berlin, Deutschland

 

20.  Patient management bei pulmonal-arteriellen Hypertension.

Rare Diseases, 1. Mariazeller Gesundheitsdialog

October 15, 2010, Mariazell, Austria

 

21.  Schwierigkeit bei der Diagnosestellung der CTEPH.

ÖGIM 2010,

November 19, 2010, Vienna, Austria

 

22.  Pulmonal-arterielle Hypertension; Ursache und Therapie.

Gender Kardiologie-Die Frau im Mittelpunkt der kardialen Erkrankung

January 22, 2011, Langenlois, Austria

 

23.   Parenteral prostanoid therapy-initiation, patient selection, treatment algorithms

Pulmonary Hypertension Academy

March 18, 2011, Vienna, Austria

 

24.  Timing of prostacyclin treatment- long-term tolerability, dosing and survival with first-line subcutaneous treprostinil for severe pulmonary hypertension.

6th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease

March 23, 2011, London, England

 

25.  Subkutanes Treprostinil bei PAH.

Pneumoupdate 2011

June 10, 2011, Igls, Austria

 

26.  Subkutanes Treprostinil bei PAH-besser als ihr Ruf.

PH-Dach-Wintersymposium 2011

December, 8, 2011, Heidelberg, Germany

 

27.  Managing the Right Ventricle in Pulmonary Hypertension: from research bench to the clinical practice.

Gulf Thoracic Dubai

March 16, 2012, Dubai, UAE.

 

28.  Chronisch Thromboembolische Pulmonale Hypertension (CTEPH).

Open Air Lunge

May 4, 2012, Vienna, Austria.

 

29.  Parenteral Prostanoid Therapy-Initiation, Patient Selection and Treatment Algorithms

5th PH Academy

October 12, 2012, Vienna, Austria.

 

30.  Asymmetric dimetyhlarginine, a biomarker for the effect of drug Therapy in Pulmonary Hypertension.

Conference of European Respiratory Society

September 3, 2012, Vienna, Austria.

 

31.  The long-term prognostic value of extracted thrombus and hemodynamics in Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Conference of European Respiratory Society

September 3, 2012, Vienna, Austria.

 

32.  Non-PAH-Pulmonary Hypertension. Current Therapeutic Options.

Polish Respiratory Society Congress.

October 19, 2012, Cracow, Polen.

 

33.   Asymmetric dimetyhlarginine, a biomarker for the effect of drug Therapy in Pulmonary Hypertension.

Scientific Session of American Heart Association

November 5, 2012, Los Angeles, USA.

 

34.  Lungenhochdruck- von Genf bis Nizza. Diagnose und Prognose.

5. Volibris Jahrestagung

April 20, 2013, Vienna, Austria

 

35.  Long-term Follow-Up after Pulmonary Endarterectomy.

Vienna Chronic Thromboembolic Pulmonary Hypertension Academy

May 7, 2014, Vienna, Austria.

 

36.   Neue Ziele und Optionen in der Pulmonalen Hypertension.

KH-Pharmazie

June 14, 2014, Vienna, Austria.

 

37.   Lungenembolie und Chronisch Thromboembolische Pulmonale Hypertension – worauf muss ich achten?

Thrombosedialog 2014

March 29, 2014, Fuschl am See, Austria.

 

38.  PAH-Update

KH-Tulln

October 14, 2014, Tulln, Austria.

 

39.   Exercise based Rehabilitaiton for Pulmonary Arterial Hypertension (PAH).

Arab Health Congress 2015.

January 27, 2015, Dubai, UAE.

 

40.   Pulmonary Hypertension – Echo perspectives.

Echo Dubrovnik 2015

May 17, 2015, Dubrovnik, Croatia.

 

41.  Prostanoid therapy: identifying responders and achieving rapid optimisation of dose.

Conference of European Respiratory Society 2015.

September 28, 2015, Amsterdam, Nederland.

 

42.   Parenteral Prostanoid Therapy – Initiation, Patient Selection, Treatment Algorithms

9th PH Academy

October 22, 2015, Vienna, Austria

 

43.   Many Years of Experience with Treprostinil in Vienna

PAH Meeting Warsaw

October 16, 2015, Warsaw, Polen.

 

44.  Pulmonale Hypertension und kardiale Dekompensation.

Österreichische Kardiologoische Gesellschaft Jahrestagung 2016

June 2, 2016, Salzburg, Österreich

 

45.  Pulmonary Hypertension-un update.

6th Congress of the Bulgarian Respiratory Society

June 11, 2016, Varna, Bulgarien

 

46.   Ambition Studie.

GSK Veranstaltung.

June 15, 2016, Vienna, Austria.

 

47.  Parenteral Prostanoid Therapy – Initiation, Patient Selection, Treatment Algorithms

10th PH Academy

September 21, 2016, Vienna, Austria

 

48.  A case of lifelong myocardial ischemia.

10th PH Academy

September 22, 2016, Vienna, Austria

 

49.  Selexipag (Uptravi ®) – erster oraler Prostazyklinrezeptor Agonist als Ersatz für Pumpen?

Kardiologie Live.

September 29, 2016, Vienna, Austria

 

50.  Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary    hypertension – a new hope for inoperable patients.

6th Slovenian Pneumology Congress

October, 7, 2016, Bled, Slovenia

 

51.   Pulmonary hypertension – news

48th Croatian Pneumology Congress

October, 14, 2016, Zadar, Croatia

 

52.  Parenteral prostanoid therapy-initiation, patient selection, treatment algorithms

11th PH Academy

March 15, 2017, Vienna, Austria

 

53.   A case of life-long myocardial ischemia

12th PH Academy

June 22, 2017, Vienna, Austria

 

54.  Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension (CTEPH)

Hot topics in PAH La Paz

September 20, 2017, Madrid, Spain

 

55.  Atypische PAH, Kardialer Phänotyp

41. Jahrestagung der ÖGP und der 1. Jahrestagung der ÖGTC

Oktober 4, 2017, Innsbruck, Austria

 

56.  Case and CTEPH team discussion

Training Meeting in Chronic Thromboembolic Pulmonary Hypertension

October 26, 2017, Vienna Austria

 

57.  Management of advanced pulmonary arterial hypertension from up-front combination therapy to lung transplantation

PAH Summit

May, 2, 2018, Belgrade, Serbia

 

58.  Management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

May, 16, 2018, Skopje, Macedonia

 

59.  Klinischer Verdacht auf Rechstherzproblematik

Österreichische Kardiologische Gesellschaft, Jahrestagung 2018

Juni, 7, 2018, Salzburg, Austria

 

60.  Pulmonale Hypertension – One size fits all?

ÖGIM 2018

September 22, 2018, Salzburg, Austria

 

61.  Vienna Long-term Experience with s.c. Treprostinil – Tips and Tricks

7th International Congress of the Swiss Society for Pulmonary Hypertension

November 9, 2018, Genf, Schweiz

 

62.  Interventionelle Therapie der CTEPH

21. Kardiologie-Kongress Innsbruck,

March 7, 2019, Innsbruck, Austria

 

63.   New treatments in CTEPH: What do the latest data suggest?

3rd International Pulmonary Vascular Disease Meeting

May 4, 2019, Istanbul, Turkey

 

64.  PAH-CHD. Impulsvortrag&Fallbeispiel

Nationales PH-Forum.

May 24, 2019, Wien, Austria.

 

65.  PH Board case. Different applications of prostacyclin-real life experience.

13th PH Academy

June 14, 2019, Wien, Austria.

 

66.  Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension.

ERS Congress 2019.

September 29, 2019, Madrid, Spain.

 

67.  Chair d. Session and Interventionelle Therapie der CTEPH.

Fokus Lungenhochdruck.

Oktober 19, 2019, Mondsee, Austria.

 

68.  Treatment modalities for inoperable CTEPH.

Regional summit: Diagnosis and Management of Pulmonary Hypertension.

Oktober 25, 2019, Novi Sad, Serbia.

 

69.   Diagnostischer Algorithmus bei PAH.

PH Infotag, Wien.

Oktober 24, 2020, Wien, Austria.

 

70.  PAH-frühe Zuweisung & Diagnose, aktuelles Behandlungschema.
Im Fokus seltene Erkrankungen. Billrothhaus, Wien. November 4, 2020.

 

71.  Role of inflammation in chronic thromboembolic pulmonary hypertension (CTEPH).

7th Slovenian Pneumology Congress joined with Allergology and Immunology congress.

Dezember 11, 2020.

 

72.  How should we screen pulmonary hypertension in connective tissue diseases?
4th International Pulmonary Vascular Disese Meeting. June, 3, 2021

 

73.  Dyspnoe unter Triple Therapie, was nun? Nationales PH-Forum. October 15, 2021.

 

74.  Lungenhochdruck und Begleiterkrankungen. Infotag Wien. November 14, 2021.

 

75.  PAH – Risk scoring driving treatment decisions? 13th European PH Meeting. November 27, 2021.

 

76.  Aus der Sicht der Kardiologin: Hot topics: RACE Daten//
medizinische und multimodale Therapie. Up-to-date bei CTEPH-Highlights vom
ICC Kongress 2021. December 16, 2021.

 

77.   Portopulmonary hypertension-case. PH Academy. June 2, 2022.

 

78.   Interventionelle Technik bei (sub)massiver Pulmonalembolie. 53. Jahrestagung
der ÖGIAIN-DGIIN. June 23, 2022.

 

79.  Young, female, syncope: What do I do? Cardio Update Europe. July 2, 2022.

 

80.  Treatment modalities in chronic thromboembolic pulmonary hypertension
(CTEPH). ACHD, PAH and Pregnancy. September 3, 2022.